Oct 7 (Reuters) - Merck (MRK.N), opens new tab is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off ...

A class-action lawsuit claims Merck overcharged for a less potent mumps vaccine, violating the Sherman Act. The District Court denied Merck's summary judgment, acknowledging ethical issues but ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the study, which involved infants up to 15 months old, and will form the basis of regulatory filing to ...

Merck Underscores Continued Commitment to Fighting Infectious Diseases with More than 40 Data Presentations Across Vaccines, Antibacterials and Antivirals, Including Respiratory Syncytial Virus ...

The first case of rabies exposure in Ontario since 1967 was reported a month ago. News reporting pegs the cause as suspected exposure to a bat found inside a child’s room while the family was ...

2024--New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio We recently compiled a list titled 7 Best Cheap Stocks to ...

Merck & Co. escaped antitrust claims by a group physicians who alleged that they bought the company’s mumps vaccine at inflated prices because it deceived the government to maintain its monopoly on ...

Oct. 7, 2024 — Over the past decade, decreasing vaccination rates now threaten the huge beneficial impacts of vaccinations in the U.S. and globally. Researchers discuss the multifactorial ...

Formaldehyde in vaccines has been reported to exacerbate hand eczema, as described in a single case report. [32] However, no other cases of formaldehyde-induced cutaneous reactions from vaccine ...